Cargando…

A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy

We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17 mm × 15 mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography revealed stenosis of the main pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitta, Toshikatsu, Fujii, Kensuke, Kataoka, Jun, Tominaga, Tomo, Kawasaki, Hiroshi, Ishibashi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855735/
https://www.ncbi.nlm.nih.gov/pubmed/27111877
http://dx.doi.org/10.1016/j.ijscr.2016.04.013
_version_ 1782430402770632704
author Nitta, Toshikatsu
Fujii, Kensuke
Kataoka, Jun
Tominaga, Tomo
Kawasaki, Hiroshi
Ishibashi, Takashi
author_facet Nitta, Toshikatsu
Fujii, Kensuke
Kataoka, Jun
Tominaga, Tomo
Kawasaki, Hiroshi
Ishibashi, Takashi
author_sort Nitta, Toshikatsu
collection PubMed
description We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17 mm × 15 mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography revealed stenosis of the main pancreatic and common bile ducts caused by a mass-neighboring cyst. Based on these findings, we performed subtotal stomach-preserving pancreaticoduodenectomy. The patient demonstrated a good postoperative course, and was discharged from our hospital in remission 49 days after the surgery. Pathological findings confirmed that it was anaplastic pancreas carcinoma (giant cell type). After the surgery, we performed S-1 adjuvant chemotherapy 100 mg/day for four weeks, repeated similarly every six weeks for a total of four courses. We have followed this case for over 2 years so far with adjuvant chemotherapy, and no recurrence or metastasis has been revealed. Adjuvant chemotherapy with S-1 in patients with resected anaplastic carcinoma of the pancreas is also recommended as a result of Japan Adjuvant Study Group of Pancreatic Cancer 01(JASPAC-01) like the ordinary pancreatic ductal carcinomas. There is a possibility to achieve long-term survival in cases in which multidisciplinary treatment such as a curative resection and adjuvant chemotherapy are performed.
format Online
Article
Text
id pubmed-4855735
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48557352016-05-24 A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy Nitta, Toshikatsu Fujii, Kensuke Kataoka, Jun Tominaga, Tomo Kawasaki, Hiroshi Ishibashi, Takashi Int J Surg Case Rep Case Report We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17 mm × 15 mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography revealed stenosis of the main pancreatic and common bile ducts caused by a mass-neighboring cyst. Based on these findings, we performed subtotal stomach-preserving pancreaticoduodenectomy. The patient demonstrated a good postoperative course, and was discharged from our hospital in remission 49 days after the surgery. Pathological findings confirmed that it was anaplastic pancreas carcinoma (giant cell type). After the surgery, we performed S-1 adjuvant chemotherapy 100 mg/day for four weeks, repeated similarly every six weeks for a total of four courses. We have followed this case for over 2 years so far with adjuvant chemotherapy, and no recurrence or metastasis has been revealed. Adjuvant chemotherapy with S-1 in patients with resected anaplastic carcinoma of the pancreas is also recommended as a result of Japan Adjuvant Study Group of Pancreatic Cancer 01(JASPAC-01) like the ordinary pancreatic ductal carcinomas. There is a possibility to achieve long-term survival in cases in which multidisciplinary treatment such as a curative resection and adjuvant chemotherapy are performed. Elsevier 2016-04-23 /pmc/articles/PMC4855735/ /pubmed/27111877 http://dx.doi.org/10.1016/j.ijscr.2016.04.013 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nitta, Toshikatsu
Fujii, Kensuke
Kataoka, Jun
Tominaga, Tomo
Kawasaki, Hiroshi
Ishibashi, Takashi
A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
title A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
title_full A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
title_fullStr A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
title_full_unstemmed A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
title_short A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
title_sort case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after s1 postoperative adjuvant chemotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855735/
https://www.ncbi.nlm.nih.gov/pubmed/27111877
http://dx.doi.org/10.1016/j.ijscr.2016.04.013
work_keys_str_mv AT nittatoshikatsu acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT fujiikensuke acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT kataokajun acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT tominagatomo acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT kawasakihiroshi acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT ishibashitakashi acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT nittatoshikatsu caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT fujiikensuke caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT kataokajun caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT tominagatomo caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT kawasakihiroshi caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy
AT ishibashitakashi caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy